ZBH Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.…
Industry Peers
Medical DevicesKey Statistics
About Zimmer Biomet Holdings (NYSE: ZBH)
›
Zimmer Biomet Holdings (NYSE: ZBH) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 17,000 employees.
The shares were at 101.47 USD on 19 November 2026, up 13.5% over 52 weeks. Its 52-week range is 79.12 USD to 112.54 USD: the price is 9.8% below the high and 28.2% above the low.
At a market capitalisation of 19.20B USD, it trades at 25.6 times trailing earnings and 11.3 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.4, so ZBH is valued in line with them. It pays a dividend yielding 0.93% (it pays out 24% of its earnings), against a median of 2.41% among the dividend payers in that peer group.
Zimmer Biomet Holdings reports return on equity of 5.6%, an operating margin of 16.7% and revenue up 3.1% year over year.
Its debt exceeds its cash by 7.23B USD, a debt-to-equity ratio of 0.59. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 21 analysts cover the stock, with an average rating of Buy; their mean price target of 117.38 USD is 15.7% above the current price. The next earnings report is expected on 10 February 2027.